Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was ...

Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home observational real-world evidence initiative supporting individuals with IgA ...

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...

The firm, which notes that Vera is conducting the Phase 3 ORIGIN 3 study of 150 mg atacicept in patients with IgAN while utilizing at-home administration with once-weekly dosing, reiterates a Buy ...

Vera stock dropped after Otsuka announced plans for accelerated approval of sibeprenlimab. Learn why VERA stock is a Hold.

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic ...

Haseeb Ahmad brings over 25 years of leadership experience in life sciences, most recently serving as President of Novartis ...

Despite potential volatility ahead of the readouts, “We continue to recommend the stock as the profile is greatly derisked & will benefit from first-ish mover advantage in IgAN, a field ...

aimed at treating IgA nephropathy (IgAN), a kidney disease. The Phase 1/2 study demonstrated significant reductions in key markers of disease activity and proteinuria, a sign of kidney damage.